背景: 免疫疗法组合可能是克服对现有疗法的耐药性的有希望的策略。AFM24是一类第一个双特异性四价先天性细胞增殖剂,结合先天性效应细胞(NK细胞和...查看全文
Affimed(AFMD)06-07 05:15
$Affimed(AFMD)$ 6-K/A [Amend] Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001193125-24-156194 Act: 34 Size: 77 KB 网页链接查看全文
Affimed(AFMD)05-28 18:55
$Affimed(AFMD)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001193125-24-147572 Act: 34 Size: 179 KB 网页链接查看全文
Affimed(AFMD)06-12 20:05
$Affimed(AFMD)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001193125-24-159605 Act: 34 Size: 429 KB 网页链接查看全文
Affimed(AFMD)06-27 04:55
$Affimed(AFMD)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001193125-24-169160 Act: 34 Size: 38 KB 网页链接查看全文
Affimed(AFMD)06-03 18:15
$Affimed(AFMD)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001193125-24-152290 Act: 34 Size: 41 KB 网页链接查看全文
Affimed(AFMD)05-24 05:25
$Affimed(AFMD)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001193125-24-146116 Act: 34 Size: 37 KB 网页链接查看全文
Spica2021-09-02 05:41
要是有个细胞治疗的指数基金就好了,$Affimed(AFMD)$ $Tcr2 Therapeutics(TCRR)$ $NexImmune(NEXI)$查看全文
Spica2021-07-18 19:54
回复@Takeabreak: 我问了下一位做干眼症的朋友,他是这么回复的“”Eysuvis 应该还不错,但不会成为重磅。重要的原因:lotemax一直被off label用作治疗干眼,$Kala制药(KALA)$ 只是改了一个剂型,把off label变成approved。Lotemax医生可以随便开的,会一定程度限制了Eysuvis销售“//@Takeabreak:...查看全文
Takeabreak2021-06-18 22:39
$安帝君斯(AGEN)$ $Kala制药(KALA)$ $Affimed(AFMD)$ BCYC, CGEN 这些都很强势!守住不动,同时间 XBI往下0.8%+。AMRS更是往上1%。吹票时间到了!!查看全文
Takeabreak2021-05-07 11:14
$Affimed(AFMD)$ 已回到将近一个月爆发前的价位(76%换手)。等XBI回100,继续缓慢加仓,AFMD,HOOK,ADAP, CRIS,PRQR查看全文
Takeabreak2021-04-28 21:59
$Adma生物制品(ADMA)$ 在角落里躺了很久了,时不时来一炮,上次增发3.5,大佬都增持,接着就一直萎靡不振,估计这次又是昙花一现。反正死拿。成本2.8 $安帝君斯(AGEN)$ $Affimed(AFMD)$查看全文
Takeabreak2021-04-27 12:49
$安帝君斯(AGEN)$ XBI一个月内,3次考验126,合格通过,前景一片大好哇!祝贺大家都顺利经受住了折磨!接下来呢?搞起来!$Affimed(AFMD)$ $工艺酿酒联盟(HOOK)$ BCYC, 都加仓了,1个月后武林大会开奖查看全文
$Affimed(AFMD)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001193125-24-169160 Act: 34 Size: 38 KB 网页链接
$Affimed(AFMD)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001193125-24-159605 Act: 34 Size: 429 KB 网页链接
$Affimed(AFMD)$ 6-K/A [Amend] Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001193125-24-156194 Act: 34 Size: 77 KB 网页链接
$Affimed(AFMD)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001193125-24-152290 Act: 34 Size: 41 KB 网页链接
$Affimed(AFMD)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001193125-24-147572 Act: 34 Size: 179 KB 网页链接
$Affimed(AFMD)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001193125-24-146116 Act: 34 Size: 37 KB 网页链接
$Affimed(AFMD)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001193125-24-080581 Act: 34 Size: 168 KB 网页链接
$Affimed(AFMD)$ 20-F Annual and transition report of foreign private issuers [Sections 13 or 15(d)] Accession Number: 0001104659-24-040310 Act: 34 Size: 12 MB 网页链接
$Affimed(AFMD)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001193125-24-064790 Act: 34 Size: 11 KB 网页链接
$Affimed(AFMD)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001193125-24-059965 Act: 34 Size: 29 KB 网页链接